Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Proteomics International Laboratories Ltd. ( (AU:PIQ) ) has shared an update.
Proteomics International Laboratories Ltd has achieved significant milestones, including receiving ISO 15189 certification for its Australian laboratory operations, which supports the commercialization of its precision diagnostic tests like PromarkerD and PromarkerEso. The company is expanding its market presence with the national launch of PromarkerD for diabetic kidney disease prediction and PromarkerEso for esophageal cancer diagnosis in Australia, alongside preparations for the PromarkerEndo test for endometriosis. These developments, coupled with a strategic go-to-market approach embracing telehealth trends, position the company for potential partnerships and revenue growth in the precision diagnostics sector.
The most recent analyst rating on (AU:PIQ) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Proteomics International Laboratories Ltd. stock, see the AU:PIQ Stock Forecast page.
More about Proteomics International Laboratories Ltd.
Proteomics International Laboratories Ltd is a pioneer in precision diagnostics, focusing on the development of novel diagnostic tests using its proprietary Promarker® biomarker discovery platform. The company operates within the precision medicine industry, offering products that address significant unmet medical needs. It is involved in the commercialization of precision diagnostics, development of diagnostic tests, and providing specialist analytical services.
Average Trading Volume: 337,645
Technical Sentiment Signal: Sell
Current Market Cap: A$57.29M
Find detailed analytics on PIQ stock on TipRanks’ Stock Analysis page.